Monday, August 31, 2026

Less Than One Hour Before The Market Open, Cronos Group Is Up By 5%

Less Than One Hour Before The Market Open, Cronos Group Is Up By 5%

(VIANEWS) - The NASDAQ opens in less than one hour and Cronos Group's pre-market value is already 5.9% up.

Cronos Group's last close was $2.88, 9.09% above its 52-week high of $2.64.

The last session, NASDAQ finished with Cronos Group (CRON) rising 8.68% to $2.88. NASDAQ jumped 0.23% to $16,277.46, following the last session's upward trend on what was a somewhat positive trend exchanging session.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Earnings Per Share

As for profitability, Cronos Group has a trailing twelve months EPS of $-0.3.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -6.3%.

Moving Average

Cronos Group's value is way above its 50-day moving average of $2.09 and way higher than its 200-day moving average of $1.96.

Yearly Top and Bottom Value

Cronos Group's stock is valued at $2.88 at 09:28 EST, higher than its 52-week high of $2.64.

More news about Cronos Group (CRON).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com